Daily topical application of chlorhexidine gluconate to the skin in dogs and its impact on skin barriers and cytotoxicity.

In recent years, the importance of using local disinfectants instead of systemic antibiotics for the treatment of infectious skin diseases to prevent the emergence of resistant bacteria has become widely recognized. Chlorhexidine gluconate (CHG) is commonly used in veterinary antibacterial shampoos; however, the daily topical application of diluted CHG solutions has also been adopted. Despite its widespread use, few studies have investigated the effects of CHG on the canine skin barrier.

Impact of depth of body cavity at the upper-right portion of the abdomen on open and laparoscopic liver resection of segment 7.

Purpose: The impact of body-cavity depth on open (OLR) and laparoscopic liver resection (LLR) of segment 7 remains unclear. Therefore, we investigated the influence of body-cavity depth at the upper-right portion of the abdomen on LLR and OLR of segment 7.

Methods: In total, 101 patients who underwent segment-7 liver resection over 2010-2023 were included.

Isogenic fish sperm produced by transplanting gynogenetic haploid-derived germ cells.

Artificially induced haploidy is lethal in vertebrates, although it is useful for genetic screening and genome editing due to its single set of genomes. Haploid embryonic stem (ES) cell lines in mammals contribute to genetic studies and the production of gametes derived from haploid ES cells. In fish breeding, doubled haploids (DHs) induced by artificially induced gynogenesis are used to generate isogenic gametes for cloning purposes.

Higher FIB-4 index at baseline predicts development of liver cancer in a community-based cohort with viral hepatitis.

Hepatitis B and C (HBV and HCV) testing has been performed in Japan since 2002 and is subsidized by central and prefectural governments. A follow-up program for HBV- or HCV-infected persons was started at that time in Ishikawa Prefecture. This study analyzed the long-term follow-up data from this program.

Treatment Outcomes of Tyrosine Kinase Inhibitors and Durvalumab Plus Tremelimumab After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.

Background/aim: Atezolizumab plus bevacizumab (AteBev) is widely used as a first-line treatment for advanced hepatocellular carcinoma (HCC). However, evidence regarding the optimal drug sequence following AteBev treatment is limited. This study aimed to compare the treatment outcomes between tyrosine kinase inhibitors (TKIs) and durvalumab plus tremelimumab (DurTre) following AteBev treatment.